Actualizing Risk-Adapted Thoracic Stereotactic Body Radiation Therapy with MR Guidance-Reference-Cited by-同舟云学术

Actualizing Risk-Adapted Thoracic Stereotactic Body Radiation Therapy with MR Guidance

Published:2021-09-01 Issue: Volume: Page:6-14
ISSN:2334-5446
Container-title:Applied Radiation Oncology
language:en
Short-container-title:ARO

Author:

Singer Lisa¹,Kann Benjamin H.²,Cagney Daniel N.³,Leeman Jonathan E.²,Yom Sue S.¹,Kozono David²

Affiliation:

1. University of California

2. Brigham and Women’s Hospital and Dana-Farber Cancer Institute

3. Mater Private

Publisher

Anderson Publishing, Ltd.

Reference54 articles.

1. Cancer statistics, 2020;Siegel;CA Cancer J Clin.,2020

2. Cancer of the lung and bronchus – cancer stat facts. NIH National Cancer Institute Surveillance, Epidemiology, and End Results Program. Accessed June 6, 2021. https://seer.cancer.gov/statfacts/html/lungb.html

3. Lung screening benefits and challenges: a review of the data and outline for implementation;Sands;J Thorac Oncol.,2021

4. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial;Ball;Lancet Oncol.,2019

5. Long-term results of RTOG 0236: A phase II trial of stereotactic body radiation therapy (SBRT) in the treatment of patients with medically inoperable stage I non-small cell lung cancer;>Timmerman;Rad Oncol Biol.,2014

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Widening the therapeutic window for central and ultra-central thoracic oligometastatic disease with stereotactic MR-guided adaptive radiation therapy (SMART);Radiotherapy and Oncology;2024-01